I think this is good for AMRN. Amarins Vascepa lowers hsCRP and seems to have a similar method of action ...and at significantly lower cost.
1) I suspect the IL-1 data will be significantly better HR. The vascepa HR is already limited to about HR >0.8 if I remember correctly (based on the continue at the interim). If it even has a meaningful benefit at all (trial hasn't finished yet)
2) the CRP benefits of IL-1 inhibitor are probably substantially better than 22%.